Skip to main content
IX BIOPHARMA LTD. logo

IX BIOPHARMA LTD. — Investor Relations & Filings

Ticker · 42C ISIN · SG1BD9000009 SGX Manufacturing
Open in API
Filings indexed 41 across all filing types
Latest filing 2025-11-05 Regulatory Filings
Country SG Singapore
Listing SGX 42C

About IX BIOPHARMA LTD.

https://www.ixbiopharma.com/

IX Biopharma Ltd. is a specialty pharmaceutical and nutraceutical company focused on developing and commercializing innovative therapies. Leveraging its proprietary WaferiX sublingual drug delivery technology, the company aims to improve the quality of life for patients with pain, chronic diseases, and debilitating conditions, particularly those affecting the central nervous system. A key product is Wafermine, a sublingual ketamine wafer designed for rapid, non-opioid relief of acute moderate to severe pain. The company was recently awarded a US$41 million U.S. government contract to fund Wafermine's Phase 3 clinical development and secure FDA Emergency Use Authorization. Additionally, iX Biopharma offers nutraceutical products, such as a sublingual NAD+ wafer for cellular energy production.

Recent filings

Filing Released Lang Actions
Disclosure of Interest/ Changes in Interest of Substantial Shareholder(s)/ Unitholder(s)::Changes in Interest by Substantial Shareholder - Anson Properties Pte. Ltd.
Regulatory Filings Classification · 100% confidence The document text contains only a placeholder message indicating that the PDF viewer cannot display the document content. There is no substantive content related to any financial report, announcement, or filing. The text is very short (692 characters) and does not contain any keywords or information to classify it as a specific filing type. Therefore, this document should be classified as a Regulatory Filing (RNS) as a fallback category for miscellaneous or non-classifiable filings.
2025-11-05 English
Disclosure of Interest/ Changes in Interest of Substantial Shareholder(s)/ Unitholder(s)::Changes in Interest by Substantial Shareholder - Eddy Lee Yip Hang
Regulatory Filings Classification · 100% confidence The document text contains only a placeholder message indicating that the PDF viewer cannot display the document content and provides instructions to upgrade Adobe Reader. There is no substantive content related to any financial report, announcement, or filing. The document length is very short (692 characters) and does not contain any financial data, regulatory references, or report titles. Therefore, it does not fit into any specific filing category and should be classified as a Regulatory Filing (RNS) as a fallback for miscellaneous or non-informative filings.
2025-11-05 English
General Announcement::Press Release - iX Biopharma Raises S$6.7 Million to Accelerate U.S. Expansion
Capital/Financing Update Classification · 95% confidence The document is a news release announcing that iX Biopharma has raised S$6.7 million through a share placement, exceeding their initial target. It details the amount raised, the number of shares issued, the price per share, and mentions institutional investors and the placement agent. There is no financial report, detailed financial statements, or comprehensive analysis of financial performance. The document is focused on capital raising activity and financing update. Given the content and context, this fits the category of Capital/Financing Update (CAP). The document length is short and it is not an announcement of a report publication or a certification. Therefore, the classification is CAP with high confidence.
2025-10-31 English
Placements::Proposed Placement To Raise Gross Proceeds No Less Than S$5 Million - Receipt of LQN
Capital/Financing Update Classification · 95% confidence The document is an announcement from the Board of Directors of iX Biopharma Ltd. regarding a proposed placement to raise gross proceeds of no less than S$5,000,000. It mentions the receipt of a listing and quotation notice from the Singapore Exchange Securities Trading Limited (SGX-ST) for the listing of new shares pursuant to the proposed placement. The document references previous announcements and states that further updates will be provided as appropriate. There are no financial statements or detailed financial data included, and the document is relatively short (2577 characters). It is clearly an update on a capital raising activity and the listing process, not a full financial report or earnings release. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2025-10-30 English
Placements::Proposed Placement To Raise Gross Proceeds No Less Than S$5 Million - Results of Proposed Placement
Capital/Financing Update Classification · 95% confidence The document is an announcement by IX Biopharma Ltd. regarding a proposed placement of new shares to raise gross proceeds, including details on the amount raised, use of proceeds, mandate for issuance, and listing application. It is not a full financial report but an update on capital raising activities. The content focuses on financing and share issuance rather than financial results or management discussion. Therefore, it fits the category of Capital/Financing Update (CAP). The document length (7771 characters) and detailed financial use of proceeds support this classification with high confidence.
2025-10-28 English
General Announcement::Proposed Placement To Raise Gross Proceeds No Less Than S$5 Million - Entry Into Placement Agreement
Capital/Financing Update Classification · 95% confidence The document is an announcement by iX Biopharma Ltd. regarding a proposed placement to raise gross proceeds of no less than S$5,000,000 through a placement agreement. It details the terms of the placement, the placement price, conditions precedent, lock-up period, rationale for the placement, and intended use of proceeds. The content focuses on fundraising activities and capital structure changes. There is no indication that this is a full financial report, audit report, or earnings release. The document is not a regulatory filing or announcement of voting results, nor is it related to management changes or legal proceedings. The detailed description of the placement agreement and capital raising clearly fits the category of Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement or a report publication announcement. Therefore, the appropriate classification is Capital/Financing Update (CAP) with high confidence.
2025-10-28 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.